Objective: Altered autonomic activity has been implicated in the development of cardiac dysfunction during seizures. This study investigates whether intervening in seizure progression with diazepam will reduce seizure-induced cardiomyopathy.
| INTRODUCTION
Status epilepticus (SE) is loosely defined as single or multiple recurring seizures lasting a minimum of 5-10 minutes with no recovery in between. Due to the high mortality rate, SE is regarded as a medical emergency, and delays in resolving SE result in poor clinical outcomes. 1 Despite antiepileptic intervention with multiple pharmacological interventions, the prognosis is poor, with mortality rates of 20%-48% reported within 30 days after the initial convulsive activity. 2 Cardiovascular injury is strongly implicated in this pathology, [3] [4] [5] [6] with tachycardia prominently reported.
Acutely, tachycardia provokes hemodynamic changes, reducing coronary blood flow and cardiac output, while increasing myocardial oxygen demand. Failure to acutely control this pathology will inevitably contribute to the development of myocardial ischemia and arrhythmias, and can amplify the risk of sudden cardiac death. Additionally, ictal electrocardiographic (ECG) wave abnormalities are commonly reported during seizures, with potentially fatal arrhythmias, such as ventricular fibrillation and asystole, occurring in 6%-13%. 7, 8 Clinically, it is important that these cardiac abnormalities are attenuated, with priority given to those changes associated with risk factors for sudden cardiac death, such as tachycardia and corrected QT (QTc) prolongation. 9 Death from cardiac injury can also occur in the postictal period and is believed to be due to an imbalance in autonomic function producing cardiovascular complications, such as lethal arrhythmias or cardiac arrest. 5, 7 Randomized controlled trials in SE have provided evidence of a high therapeutic success rate in controlling seizure activity with benzodiazepines, which has led to the use of diazepam, midazolam, or lorazepam as first-line antiepileptic interventions in patients with SE. 1, 10 Diazepam potentiates the inhibitory effect of c-aminobutyric acid (GABA) at GABA A receptors to increase the Cl -current, thereby increasing the threshold of neuronal firing. 11 However, the action of diazepam is rapid and short-lived, and only serves to arrest the seizure without addressing the systemic consequences of seizure. Therefore, coadministration of diazepam with the sympatholytic atenolol was investigated in this study. Atenolol is a hydrophilic b 1 antagonist that acts directly on the heart to block the effect of sympathetic stimulation. 12 Clinical studies have shown that atenolol is effective at attenuating ischemic damage and improving left ventricular function. 13, 14 Prophylactic atenolol administration has been shown to prevent tachycardia and protect against seizure-induced QTc prolongation in rat models of SE. 6, 15 Previous work by our group demonstrated that SE resulted in an immediate elevation in sympathetic activity, leading to structural cardiac damage and seizure-induced cardiomyopathy. 5 Our group also confirmed that pretreatment with sympatholytics could protect the heart during seizure. 4, 6 This current study broadens our understanding by investigating whether intervening in seizure progression with diazepam has any beneficial impact on the associated development of cardiomyopathy in seizure. Second, this study examines the hypothesis that combining atenolol with diazepam, as an intervention after seizure onset, will combat cardiac injury during SE. s.c., once daily) were administered for the remainder of the study (7 days). Control animals were administered intrahippocampal saline and an equivalent volume of subcutaneous saline at 60 minutes and then daily for the remainder of the study. Simultaneous EEG/ECG and behavioral activity were recorded for 3 hours immediately following seizureinduction and for 60 minutes at 24 and 48 hours, and at 7 days post-KA. Blood pressure (BP) was taken over the course of the study, and at 7 days animals underwent either echocardiography (n = 6/group) or assessment of latency to aconitine-induced arrhythmias (n = 6/group). 
| Surgical implantation of telemetric transmitters and drug cannulae

| ECG and BP analysis
ECG data were analyzed using the LabChart v.6 Pro ECG Analysis software module to assess heart rate (HR) and QT intervals. The end of the T wave was determined to be when the wave returned to the isoelectric line. Data were analyzed in 10-minute blocks over the 3-hour observation period. The QTc interval was calculated to adjust for rate by applying the Mitchell algorithm to the QT interval recordings, where QTc = QT 0 /(RR/100) 1/2 . This algorithm is designed to correct for the higher HR and altered QRS-T wave morphology in rodents. In a subset of animals (n = 6/group), arterial systolic BP was recorded prior to seizure induction and at regular intervals post-KA, using a noninvasive tail-cuff monitor (ADInstruments, Dunedin
New Zealand) and recorded as the mean of 4 repeat BP measurements using LabChart v.6 software.
| Arrhythmia risk
Following the 7-day behavioral study, a subgroup of rats (n = 6/group) were administered a bolus injection of the proarrhythmogenic agent aconitine (0.5 mgÁkg À1 , s.c.) to assess vulnerability to arrhythmias. 5 The latency from aconitine administration to presentation of ECG arrhythmias was recorded in each animal. These included first premature ventricular contraction (PVC; premature QRS with no P wave), bigeminy (2 or more PVCs), ventricular tachycardia (a series of 4 PVCs for each P wave and corresponding QRS complex), and ventricular fibrillation (no discernible rhythm). 20 Rats were sacrificed at the presentation of ventricular fibrillation in accordance with the conditions set out in the animal ethics approval.
| ECG
Seven days following KA or saline administration a separate subgroup of animals (n = 6/group) were allocated to cardiac imaging studies. Transthoracic echocardiography was performed following Domitor sedation to determine left ventricular dimensional and functional parameters across the parasternal short axis view using the Vivid E9 ultrasound system (GE Healthcare UK, Buckinghamshire, UK). Left ventricular end-systolic and end-diastolic diameters were measured at the level of the papillary muscles 
| Histology and immunohistochemistry of myocardial injury
Following echocardiography, rats were anesthetized with halothane for cardiac histology sampling (n = 6/group). Hearts were arrested in diastole by infusing with a KCl (20 mmolÁL -1 ) depolarizing solution in 0.9% saline and perfusion-fixed (73.6 mm Hg pressure) and maintained in 10% neutral buffered formalin (24 hours). Transverse apical ventricular tissue blocks (3, 6 , and 9 mm depth from apex) were paraffin-embedded and 5-lm-thick tissue sections were prepared for staining with Martius scarlet blue (MSB), ApopTag, or CD68 staining. DNA strand breaks were assessed enzymatically using an ApopTag Peroxidase kit (Millipore, Darmstadt, Germany) to detect the presence of free DNA 3 0 -OH termini. ApopTag immunohistochemistry was performed as per the manufacturer's instructions and counterstained with Gill's hematoxylin. Sections were then dehydrated with ascending concentrations of ethanol and mounted using di-n-butyl phthalate in xylene. Cardiac macrophage infiltration (CD68) was assessed following antigen retrieval using sodium citrate buffer (10 mmolÁL ImageScope Nuclear analysis module v.9 software was used to determine the number of ApopTag-positive and CD68-positive cells, and these values were expressed as a ratio of the total stained tissue area (cellsÁmm À2 ).
| Statistics
Statistical analysis was performed using Prism v.6 (GraphPad, La Jolla, CA, USA). Behavioral data were analyzed using a Kruskal-Wallis test with Bonferroni post hoc test. EEG, ECG, and BP variables were analyzed using a 2-way repeated measures analysis of variance (ANOVA) with Bonferroni post hoc analysis. Echocardiography, histology, and arrhythmia data were analyzed with a 1-way repeated measures ANOVA comparing to baseline using Dunnett post hoc analysis. Statistical significance was determined as P < .05. Data are presented as mean AE standard deviation.
3 | RESULTS
| Seizure activity
Intrahippocampal infusion of saline in control animals produced no effect on rat behaviors or EEG activity, with animals displaying normal behaviors throughout the study ( Figure 1A ). KA administration resulted in an immediate increase in seizure behaviors (mean seizure score = 3.0 AE 0.4; F = 7.23) and EEG activity within the initial 60-minute recording period ( Figures 1A and 2 ). Seizure activity remained elevated in the saline-dosed animals, which exhibited 170 AE 83 WDS behaviors and 90 AE 47 Level 4 behaviors over the 120-minute posttreatment recording period. Seizure behaviors were still observed in the saline-treated rats up to 48 hours post-KA but returned to control levels by 7 days ( Figure 1A ). Diazepam (5 mgÁkg À1 ) administration produced an immediate drop in the mean behavioral score to 0.91 AE 2.3 (vs pretreatment score of 2.92 AE 3.4; Figure 1A ) and reduced high-amplitude EEG spiking ( Figure 2B ), leading to a 79% reduction in cumulative behavioral score compared to the saline-treated group (Table 1A) . Atenolol intervention (5 mgÁkg À1 ) produced a decrease in Level 4 seizure behaviors, resulting in a lower cumulative behavioral score and decreased seizure severity 170-180 minutes post-KA (P < .05 compared to the saline group; Table 1A and Figure 1A ). Combination therapy significantly dropped the behavioral score within 60 minutes following administration ( Figure 1A ) and reduced EEG amplitude back to baseline levels ( Figure 2D ).
Additionally, combination treatment significantly reduced the incidence of Level 4 behaviors compared to diazepam treatment alone (P < .05; F = 1.99). No rats died as a consequence of seizure or intervention over the course of the study.
| Cardiac function
Nonseizure control animals receiving intrahippocampal saline showed no significant change in HR, QTc, or systolic BP from baseline levels (mean 348 AE 30 beats per minute [bpm], 42 AE 8 milliseconds, and 97 AE 6 mm Hg, respectively). KA-induced seizures produced tachycardia (increase ≥ 20%; F = 5.36) in all animals during the initial 60 minutes ( Figure 1B ). This development was unabated by subsequent saline vehicle intervention, where HR remained elevated for the 180-minute recording period ( Figure 1B ). This rise in HR in the saline intervention group was associated with a prolongation of the QTc interval by 10%-15% 10 minutes following seizure induction, which persisted up to 48 hours ( Figure 1C ; F = 2.15). Although diazepam intervention produced a drop in seizure activity, no reduction in tachycardia (maximum HR = 483 AE 39 bpm) was observed ( Figure 1B ) in response to the anticonvulsant. Diazepam intervention equally failed to restore QTc interval, which remained significantly prolonged until the 7 day time point (61 AE 5 milliseconds; Figure 1C ). Atenolol intervention, either alone or in combination with diazepam, was effective at arresting the tachycardia, rapidly reducing HR and the QTc interval back to baseline levels. Seizure activity in the saline-treated group resulted in an increase (13%-25% compared to respective baseline) in systolic BP from the 1-hour time point until 48 hours post-KA (Figure 3 ; F = 6.41). A significant 20%-30% elevation in systolic BP was observed 1 hour after seizure induction, with this effect attenuated following atenolol intervention (Figure 3 ). Diazepam administration resulted in a further elevation in BP to 156 AE 24 mm Hg and 138 AE 12 mm Hg at 3 and 24 hours, respectively. This hypertensive effect of diazepam was prevented when diazepam was coadministered with atenolol.
ECG recordings demonstrated that there was a significant decrease in EF (by 15%) and FS (by 23%) in the saline-treated seizure animals compared to control rats (Table 1B ; F = 4.69), although no changes in left ventricular wall and internal dimensions (LVIDd, LVIDs, LVPWd, and LVPWs) were observed at 7 days. Diazepam offered no protection to left ventricular parameters (P < .05 compared to control); however, atenolol administration restored EF and FS indices back to control values.
Aconitine provoked the development of arrhythmias in nonseizure control animals, with PVCs, bigeminy, and eventually ventricular fibrillation observed at 33 AE 8,
F I G U R E 1 Effect of seizure induction versus control (red line)
on maximum behavioral score (A), heart rate (beats per minute [bpm]; B), and the corrected QT (QTc) interval (C) in rats. Data are presented at 10-minute intervals over the initial 180 minutes after seizure induction and at 24 hours, 48 hours, and 7 days following the initial seizure event. Saline, diazepam, atenolol, or diazepam and atenolol were administered subcutaneously 60 minutes after seizure induction (blue dashed line). Data are presented as mean AE standard deviation (n = 12/group). *P < .05 control versus saline, + P < .05 control versus diazepam, # P < .05 control versus atenolol, Ψ P < .05
control versus diazepam and atenolol 34 AE 11, and 46 AE 8 minutes, respectively (Figure 4 ; F = 7.75, 6.73, 3.67, respectively). In the saline intervention group, seizure animals showed an increased susceptibility to benign arrhythmias, with PVCs and bigeminy onset occurring 56% and 30% earlier than in controls. These saline-treated seizure animals also had a reduced latency to potentially fatal arrhythmias such as ventricular tachycardia and fibrillation compared to control animals. Diazepam treatment failed to increase this latency, with arrhythmia development occurring significantly earlier than in the nonseizure control animals. Furthermore, the development of bigeminy occurred 35% earlier in the diazepam group than in the saline-treated seizure animals (P < .05). Atenolol and combination therapy were effective at reducing susceptibility to arrhythmias, with latency times similar to those of the control animals ( Figure 4 ). Cardiac histochemical staining with MSB at 7 days following seizure induction in saline-treated animals revealed significant evidence of fibrosis (4.7% of the left ventricular area; Figure 5G ) and reversible ischemic damage as demonstrated by myocyte vacuolization ( Figure 5B ) compared to nonseizure control hearts. Seizure activity in the saline intervention group also produced a significant increase in interfibrillar edema by 22.3% AE 6% compared to control hearts ( Figure 5H ). Ventricular myocardium in these saline-treated seizure animals also exhibited a 4-fold increase in the extent of ApopTag-positive cell staining at 7 days following seizure ( Figure 5C,D,J) . Histological Figure 5E,F,I ). Disappointingly, diazepam offered no cardiac protection against the development of myocardial fibrosis (6% AE 6%), edema (19% AE 7%), apoptosis (0.5 AE 0.2 cellsÁmm À2 ), or macrophage infiltration (58 AE 42 cellsÁmm À2 ; Figure 5 ). Atenolol, either alone or in combination with diazepam, was effective at preserving normal cardiac morphology, with no edema, apoptosis, or macrophage infiltration observed.
| DISCUSSION
This study assessed the protective value of both cardioprotective and antiepileptic intervention strategies in seizureinduced cardiomyopathy. Diazepam decreased seizure severity but had no protective effect on cardiac function. Atenolol significantly reduced cardiac dysfunction and preserved normal cardiac morphology, while also decreasing high-level seizure behaviors. Combination therapy with atenolol in addition to diazepam provided improved protection against seizure activity, while simultaneously protecting the heart in both the immediate postictal period and at 7 days following seizure induction. This improved protection with the combination therapy is particularly significant given that diazepam intervention as a monotherapy increased blood pressure and predisposed the heart to QTc prolongation and arrhythmia formation. This study demonstrated that intrahippocampal KA administration produces a progressive increase in EEG activity and seizure behaviors, such as myoclonic jerks and foaming, coinciding with the development of hypertension, tachycardia, and QTc prolongation. The elevated sympathetic responses observed during generalized seizure activity were consistent with previous findings reported in animal and clinical studies. [4] [5] [6] [7] In an anesthetized rat model, Hotta et al reported a 17% increase in HR and a two-fold increase in sympathetic nerve activity within an hour of KA (10-12 mgÁkg À1 , intraperitoneal [i.p.]) administration. 21, 22 Bealer et al 16 showed that SE, induced by lithium and pilocarpine in rats, caused significant increases in HR (~30%-35%) and BP (~25%-30%) within 60 minutes, which coincided with elevated troponin I levels, indicative of acute myocardial injury. The QTc interval (~30%-40%) was also prolonged in these animals at 10-14 days post-SE and was associated with an increased risk of aconitine-induced arrhythmias. The cardiac pathology reported here is also similar to the presentations reported in both animal and A, Behavioral activity during the 120 minutes following intervention therapy versus control (no seizure). The cumulative score was the sum of the maximum behavior every minute. The total numbers of WDS, and Level 4 and Level 5 behaviors were recorded (n = 12/group). B, Cardiac function assessed using echocardiography 7 days following seizure and therapeutic intervention versus nonseizure control (n = 6/group). Data are presented as mean AE standard deviation. Diaz.+Aten., diazepam and atenolol; EF, ejection fraction; FS, fractional shortening; WDS, wet dog shakes. a P < .05 compared to control, b P < .05 compared to saline.
T A B L E 1 Behavioral activity and cardiac function following seizure induction and therapeutic intervention F I G U R E 3 Effect of seizure (red line) and intervention therapy (with saline, diazepam, atenolol, or diazepam and atenolol) versus control (no seizure) on systolic blood pressure (sBP) in rats. Data are presented as mean AE standard deviation (n = 6/group). *P < .05 control versus saline, + P < .05 control versus diazepam, # P < .05 control versus atenolol, Ψ P < .05 control versus diazepam and atenolol clinical studies. [3] [4] [5] [6] 23 Structural changes have been found in 33% of hearts from epileptic patients with evidence of perivascular and interstitial fibrosis, reversible myocyte vacuolization, leukocytic infiltration, and edema discovered at postmortem. 3, 23 This cardiac injury, particularly the appearance of fibrotic scarring, is associated with an increased susceptibility to arrhythmias and reduced contractile function (decreased EF and FS). Diazepam intervention rapidly reduced high-amplitude EEG spiking and significantly decreased seizure behaviors but offered no cardioprotective benefit. Previous studies have reported inconsistent effects for diazepam on cardiovascular function in seizure models. [24] [25] [26] Seizure attenuation with diazepam in the current study surprisingly failed to reduce the seizure-induced tachycardia and actually extended the incidence of hypertension, QTc prolongation, and arrhythmia formation. Diazepam has been shown to affect phosphodiesterase (PDE) activity, specifically inhibiting the cardiac isoform PDE4. 27 Additionally, diazepam has been reported to potentiate the chronotropic and inotropic responses to noradrenaline and adrenaline of cardiac breceptors in rat ventricular myocardium. 28 These direct cardiac effects of diazepam could escalate second messenger levels and may serve to override any beneficial effects obtained from centrally ablating seizure activity. The addition of atenolol in this combination treatment may therefore have served to indirectly counteract the deleterious positive inotropic and chronotropic effects produced by diazepam. Investigation into the pharmacological mechanisms involved in the cardiovascular effects of diazepam are currently being explored by our group. The increased HR produced by diazepam observed in the current study may be a dose-related effect. Gerold et al 25 reported that 0.3-1 mgÁkg À1 of diazepam had no influence on HR, whereas 10 mgÁkg À1 diazepam produced a rapid and sustained increase in HR in dogs. Cardiac arrhythmias and tachycardia have been sparsely reported in humans following administration of diazepam. 26, 29, 30 This lack of clinical information is not surprising, however, given the difficulties of monitoring patients with severe seizure presentations. Conversely, blockade of peripheral benzodiazepine receptors reduced ventricular arrhythmias following myocardial ischemia and reperfusion in dogs. 31 In the current study, we did not observe a direct association between diazepam administration and ECG abnormalities; however, the prolonged tachycardia could enhance the cardiac injury, leading to an increased susceptibility to arrhythmia formation. This study demonstrates that intervention therapy with atenolol was effective in reducing tachycardia and hypertension during seizures. Atenolol also preserved left ventricular function and prevented fibrotic deposition while decreasing susceptibility to aconitine-induced arrhythmias at 7 days. This supports clinical data indicating that atenolol reduces the incidence, frequency, and severity of ventricular arrhythmias by increasing the ventricular fibrillation threshold. 13 Similarly, studies by Bealer and coauthors showed that a bolus injection of atenolol (1 mgÁkg À1 , intravenous) given prior to and 90 minutes following the induction of seizure preserved cardiac output and prevented QTc prolongation. 15, 16 Our previous findings demonstrated that the sympatholytics clonidine and . Data are presented as mean AE standard deviation (n = 6/group). *P < .05 compared with the control group. Scale bars = 100 µm atenolol were cardioprotective when administered prior to SE induction with systemic KA. These results lead us to strongly suggest that atenolol has therapeutic benefit and should be considered for combination use with current antiepileptic medications in hemodynamically stable patients.
As demonstrated in the present study utilizing an improved seizure model, combination intervention therapy with diazepam and atenolol following seizure induction proved effective at protecting both the heart and the brain during sustained seizure activity. Chugh et al reported a similar effect where diazepam administration was effective at reducing aminophylline-induced seizures in mice but offered no protection against mortality. However, when diazepam (10 mgÁkg À1 ) was coadministered with atenolol (5 mgÁkg À1 ), it produced complete protection against convulsions and sudden death. 32 The clinical significance of the anticonvulsant effect of the b-blockers is controversial. , i.p) either alone or in combination with diazepam, it failed to offer the same benefit over the short 60-minute recording period. A similar effect was reported in an electroshock convulsion model in rats, where propranolol (5 mgÁkg À1 , i.p.) and metoprolol (50 mgÁkg À1 , i.p.) administration prior to seizure induction increased the anticonvulsant effect of diazepam, whereas atenolol (10 mgÁkg À1 , i.p.) produced no further protection when measured as a 60-second hind limb extension test. 34 These observations are supported by our current study findings showing that atenolol did not significantly reduce seizure severity until 170-180 minutes after seizure induction (110 minutes posttreatment). The role of b-adrenergic receptors in epilepsy still remains unclear. 35 The hydrophilic nature of atenolol should prevent this drug from traversing the blood-brain barrier unless the barrier is compromised by severe seizure. However, unlike published prophylactic studies where atenolol was administered 30-120 minutes prior to seizure induction, 6, 15, 16 therapeutic intervention in the current study was initiated 60 minutes after seizure induction, when the blood-brain barrier may be compromised, allowing atenolol greater access to the hippocampus. There is evidence to suggest that adrenergic receptors are associated with proconvulsant effects 33, [36] [37] [38] and are distributed throughout the hippocampus, specifically CA3 and the dentate gyrus. b-adrenergic stimulation is involved in glutamate receptor modulation, via cyclic adenosine monophosphate-dependent protein kinase activation. 39, 40 Hippocampal b 1 (and b 2 ) blockade, may exert an anticonvulsant effect via reduced phosphorylation of glutamatergic a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate receptors, thereby decreasing Na + and Ca 2+ currents. 39, 40 KA increases activity in the hippocampal CA1, CA3, and dentate gyrus via activation of AMPA and kainate receptors; therefore, blockade of adrenergic stimulation in these regions may contribute to the seizure attenuation obtained in this study. The combined effect of diazepam increasing the threshold of neuronal firing, with atenolol-mediated b-adrenergic blockade in the hippocampus, appears to be acting synergistically to reduce seizure activity. However, it is equally possible that by rapidly returning hemodynamic function to normal levels following seizure, atenolol preserves cerebral perfusion and reduces the potential for seizure-associated ischemic injury. This study clearly demonstrates that protecting the heart during severe seizure episodes should be a primary concern in the therapeutic management of status epilepticus. Although conventional treatment with the antiepileptic intervention diazepam reduced the severity of seizures, diazepam failed to reduce the cardiac dysfunction and injury consequent to SE. Diazepam may also accentuate the severity of the cardiac response, increasing the risk of arrhythmia. Atenolol was effective at preserving normal cardiac function and appeared to potentiate the anticonvulsant effect of diazepam on high-level seizure behaviors. Importantly, atenolol administration also served to block the cardiac dysfunction produced by diazepam administration. Therefore, the findings of this study strongly suggest that intravenous beta blockade with atenolol should be considered as a cardioprotective adjunct intervention measure with antiepileptic therapy in hemodynamically stable patients.
